Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antibiotic resistance is a growing global health threat, with ESKAPE pathogens exhibiting multidrug resistance (MDR).
• The development of new antimicrobial therapies is lagging behind the rise of MDR bacterial infections.
• Effective preclinical models are essential for accelerating the evaluation of novel antimicrobials.

Purpose of the Study:

• To refine an existing mouse model for pulmonary Pseudomonas aeruginosa infection.
• To establish a robust preclinical tool for rapid and accurate prediction of novel antimicrobial efficacy.
• To support the development of new therapies against MDR bacterial infections.

Main Methods:

• Characterized the virulence of diverse MDR P. aeruginosa strains using 50% lethal dose (LD50) analysis and natural history studies.
• Defined standard antibiotic treatment regimens (aztreonam and amikacin) for comparator use.
• Validated the model's ability to differentiate treatment efficacy based on in vitro data.

Main Results:

• The refined mouse model demonstrated robust and reproducible data for evaluating antimicrobial efficacy.
• The model successfully predicted treatment outcomes, aligning with in vitro susceptibility data.
• Established comparator antibiotic regimens provide a benchmark for novel drug evaluation.

Conclusions:

• The validated mouse model serves as a critical tool for preclinical evaluation of novel antimicrobials against MDR P. aeruginosa.
• This improved model can expedite the drug development process and support clinical trial progression.
• Enhanced preclinical models are vital for addressing the urgent need for new antibiotics to combat resistant infections.